Andrew Hore

Andrew Hore is the publisher of AIM Journal, which is an online monthly publication covering the Alternative Investment Market.

ValiRx plans to in-licence potential breast cancer treatment

Year of consolidation for Ilika before Stereax sales take off

AIM movers: CMO downgrades guidance and Concurrent Technologies medical order

AIM movers: Great Western Mining JV and eve Sleep recovers

Serica Energy rejects Kistos bid approach

Renewable prospects for Mpac

Petropavlovsk warns of further defaults

AIM movers: Mpac suffers delays and Cornerstone FS revenue growth

AIM reversal: Fiinu’s open banking opportunity

New standard Listing: Spiritus Mundi diagnoses targets

Aquis weekly movers: Black Sea Property NAV rise and Chapel Down flat

AIM weekly movers: Tekmar recovers some of previous week’s loss

AIM movers: Science in Sport disappoints and Tekmar wins contract in Japan

Osirium Technologies momentum continues

New Aquis admission: Visum Technologies

AIM movers: Jet2 uncertainty and Simec Atlantis Energy tidal boost, plus ex-dividends

Currys cautious about short-term prospects

Persimmon housebuilding volumes decline

New AIM admission: LifeSafe Holdings

ActiveOps invests for the future

Coats buys footwear components supplier Texon

AIM movers: Savannah Resources chief exec departs, Parkmead revenue increase

AO World cash call

AIM movers: Kitwave and Equals upgrades, but forecast cut for Supreme

Why companies left AIM in June

AIM movers: Tekcapital considers Salarius float, plus Nanosynth, Jadestone Energy, Omega Diagnostics

New standard listing: Alteration Earth

Aquis weekly movers: Chapel Down marketing boss leaves

AIM weekly movers: MySale share price nearly trebles on Fraser stake buy

AIM movers: Gyllenhammar buys Rurelec stake, plus MySale, Itaconix, BlueRock Diamonds

Xpeng – the Tesla rival whose shares have rallied 315% in two months

23/11/2020

‘End of Austerity’ promise hashed out during PMQs

10/10/2018

Brexit: 5,000 City jobs could leave UK

10/10/2018

Advanced Oncotherapy shares soar after cancer treatment milestone

10/10/2018

Two reasons Travelodge backers can expect sleepless nights

24/07/2020